

Special Issue

Development of Vaccines against Tuberculosis: One Health Approach

Message from the Guest Editor

This Special Issue focuses on recent research and development of vaccines against human and animal TB. We particularly encourage you to contribute with an original article or review to highlight (i) recent advances in novel prophylactic and post-exposure TB vaccines; (ii) animal models, delivery modalities, immune responses to vaccination, and correlates of protection; (iii) development of vaccination-compatible diagnoses (DIVA); and (iv) field trials. Keywords:

- tuberculosis
- one health
- zoonosis
- vaccines
- animal models
- efficacy
- safety
- immune responses
- BCG
- DIVA

Guest Editor

Dr. Bernat Pérez de Val

Institute of Agrifood Research and Technology—Research Center for Animal Health (IRTA-CReSA), 08193 Bellaterra, Barcelona, Spain

Deadline for manuscript submissions

closed (30 November 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/55924

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).